Literature DB >> 30802228

Melanoma vaccines: clinical status and immune endpoints.

Deena M Maurer1, Lisa H Butterfield1,2,3,4, Lazar Vujanovic2.   

Abstract

It has been known for decades that the immune system can be spontaneously activated against melanoma. The presence of tumor infiltrating lymphocytes in tumor deposits is a positive prognostic factor. Cancer vaccination includes approaches to generate, amplify, or skew antitumor immunity. To accomplish this goal, tested approaches involve administration of tumor antigens, antigen presenting cells or other immune modulators, or direct modulation of the tumor. Because the success of checkpoint blockade can depend in part on an existing antitumor response, cancer vaccination may play an important role in future combination therapies. In this review, we discuss a variety of melanoma vaccine approaches and methods to determine the biological impact of vaccination.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30802228      PMCID： PMC6392068          DOI： 10.1097/CMR.0000000000000535

Source DB:  PubMed          Journal:  Melanoma Res        ISSN： 0960-8931            Impact factor:   3.599


  120 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

Authors:  Rodney A Rosalia; Esther D Quakkelaar; Anke Redeker; Selina Khan; Marcel Camps; Jan W Drijfhout; Ana Luisa Silva; Wim Jiskoot; Thorbald van Hall; Peter A van Veelen; George Janssen; Kees Franken; Luis J Cruz; Angelino Tromp; Jaap Oostendorp; Sjoerd H van der Burg; Ferry Ossendorp; Cornelis J M Melief
Journal:  Eur J Immunol       Date:  2013-08-05       Impact factor: 5.532

3.  Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Authors:  Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner
Journal:  JCI Insight       Date:  2017-04-20

4.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

5.  Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Authors:  Gerty Schreibelt; Kalijn F Bol; Harm Westdorp; Florian Wimmers; Erik H J G Aarntzen; Tjitske Duiveman-de Boer; Mandy W M M van de Rakt; Nicole M Scharenborg; Annemiek J de Boer; Jeanette M Pots; Michel A M Olde Nordkamp; Tom G M van Oorschot; Jurjen Tel; Gregor Winkels; Katja Petry; Willeke A M Blokx; Michelle M van Rossum; Marieke E B Welzen; Roel D M Mus; Sandra A J Croockewit; Rutger H T Koornstra; Joannes F M Jacobs; Sander Kelderman; Christian U Blank; Winald R Gerritsen; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

6.  Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Authors:  Christoffer Gebhardt; Alexandra Sevko; Huanhuan Jiang; Ramtin Lichtenberger; Maike Reith; Kathrin Tarnanidis; Tim Holland-Letz; Ludmila Umansky; Philipp Beckhove; Antje Sucker; Dirk Schadendorf; Jochen Utikal; Viktor Umansky
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

7.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othonas Papadopoulos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

8.  Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Ronald L Hamilton; Ashok Panigrahy; Douglas M Potter; Angela K Connelly; Sharon A Dibridge; Theresa L Whiteside; Hideho Okada
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

9.  Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

Authors:  M L Disis; J R Gralow; H Bernhard; S L Hand; W D Rubin; M A Cheever
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

Review 10.  Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.

Authors:  Robert Wesolowski; Joseph Markowitz; William E Carson
Journal:  J Immunother Cancer       Date:  2013-07-15       Impact factor: 13.751
View more
  6 in total

1.  Surgery for liver metastases from primary melanoma: a systematic review and meta-analysis.

Authors:  Mark Yeo; Yoshio Masuda; Mikel-Prieto Calvo; Marcello Di Martino; Benedetto Ielpo; Koh Ye-Xin
Journal:  Langenbecks Arch Surg       Date:  2022-10-06       Impact factor: 2.895

2.  Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.

Authors:  Lien De Beck; Robin Maximilian Awad; Veronica Basso; Noelia Casares; Kirsten De Ridder; Yannick De Vlaeminck; Alessandra Gnata; Cleo Goyvaerts; Quentin Lecocq; Edurne San José-Enériz; Stefaan Verhulst; Ken Maes; Karin Vanderkerken; Xabier Agirre; Felipe Prosper; Juan José Lasarte; Anna Mondino; Karine Breckpot
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

Review 3.  Advanced Melanoma: Resistance Mechanisms to Current Therapies.

Authors:  Alexandra M Haugh; April K S Salama; Douglas B Johnson
Journal:  Hematol Oncol Clin North Am       Date:  2020-10-26       Impact factor: 3.722

Review 4.  Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.

Authors:  Leona Yamamoto; Nicola Amodio; Annamaria Gulla; Kenneth Carl Anderson
Journal:  Front Oncol       Date:  2021-01-27       Impact factor: 6.244

Review 5.  Is immunotherapy in the future of therapeutic management of sarcomas?

Authors:  Ottavia Clemente; Alessandro Ottaiano; Giuseppe Di Lorenzo; Alessandra Bracigliano; Sabrina Lamia; Lucia Cannella; Antonio Pizzolorusso; Massimiliano Di Marzo; Mariachiara Santorsola; Annarosaria De Chiara; Flavio Fazioli; Salvatore Tafuto
Journal:  J Transl Med       Date:  2021-04-26       Impact factor: 5.531

6.  Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response.

Authors:  Saurabh K Garg; Eric A Welsh; Bin Fang; Yuliana I Hernandez; Trevor Rose; Jhanelle Gray; John M Koomen; Anders Berglund; James J Mulé; Joseph Markowitz
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.